Thursday, June 11, 2026
🇺🇸 FDA

pharma · Breast Cancer · Prostate Cancer · UTHR

United Therapeutics Europe

United Therapeutics Europe Ltd

United Therapeutics Europe patent portfolio — 3720 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
1000 Spring Street, Silver Spring, Maryland 20910, US HQ
1996 Founded
1,443 Employees
Public company Type
UTHR · NYSE Ticker
Company details
Status
Public
HQ
1000 Spring Street, Silver Spring, Maryland 20910, US
Founded
1996
Employees
1,443
Programs
1032
Drugs
612
Patents
3720
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

United Therapeutics Europe patents

3,720 pharmaceutical patents indexed for United Therapeutics Europe. 233 expire within 24 months.

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 233 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

3,720 patents

Patent portfolio

Page 45 of 78

  1. US 8518647

    Method of diagnosing poor survival prognosis colon cancer using miR-16b

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8518957

    Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8518968

    Hydrazone and diacyl hydrazine compounds and methods of use

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8513005

    DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8512755

    Compact multifunctional ligand to enhance colloidal stability of nanoparticles

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8513214

    C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8512991

    Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8507433

    Cardioprotective effects of GHRH agonists

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8506947

    Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8506961

    Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (JEV) and their use

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8501188

    Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8501912

    Filipil compositions and methods for treating cancer

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8501688

    SCGB3A2 as a growth factor and anti-apoptotic agent

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8501926

    Malaria vaccine

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8501182

    Monoclonal antibodies that react with the capsule of Bacillus anthracis

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8497249

    Fungicidal properties of three saponins from Capsicum frutescens

    Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8497393

    Process to prepare treprostinil, the active ingredient in Remodulin®

    Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8492428

    Small-molecule botulinum toxin inhibitors

    Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8486699

    Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines

    Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8481289

    Triple acting antimicrobials that are refractory to resistance development

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8481055

    Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8481255

    Scytovirin domain 1 related polypeptides

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8481048

    Methods for preparing immunogenic conjugates

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8476236

    Treatment of skin conditions by Dickkopf1 (DKK1)

    Expires Mon Jun 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8470342

    Methods of altering an immune response induced by CpG oligodeoxynucleotides

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8470888

    Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8465917

    Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells

    Expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8465749

    Polysaccharide-protein conjugate vaccines

    Expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8465743

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    Expires Mon Jun 13 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8461192

    Method of selectively inhibiting PKCiota

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8460675

    Viral chemokine-antigen fusion proteins

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8460660

    Anti-mesothelin antibodies

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8455455

    Compositions and methods for silencing genes involved in hemorrhagic fever

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8455437

    Method to predict and prevent oxygen-induced inflammatory tissue injury

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8454972

    Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8454936

    Metal chelators and methods of their use

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8455652

    Inhibitors for the soluble epoxide hydrolase

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8455454

    miR 204, miR 211, their anti-miRs, and therapeutic uses of same

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8454965

    Method for the treatment of multiple sclerosis

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8450055

    Malaria antigen screening method

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8450345

    Iminosugars and methods of treating viral diseases

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8450325

    Methods for reducing the recurrence of cardiac arrhythmia

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8445216

    Antibodies and immunotoxins that target human glycoprotein NMB

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8444996

    Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8445658

    Proteins with repetitive bacterial-Ig-like (Big) domains present in Leptospira species

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8440415

    BORIS isoforms and methods of detecting and treating disease

    Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8440411

    Differential gene expression in physiological and pathological angiogenesis

    Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8440393

    Pro-angiogenic genes in ovarian tumor endothelial cell isolates

    Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

233 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.